Shares of Altimmune, Inc. (NASDAQ:ALT – Get Free Report) were up 4.9% during mid-day trading on Friday . The stock traded as high as $9.02 and last traded at $9.01. Approximately 1,826,223 shares traded hands during mid-day trading, a decline of 52% from the average daily volume of 3,833,614 shares. The stock had previously closed at $8.59.
Wall Street Analyst Weigh In
A number of equities analysts have recently commented on the stock. HC Wainwright restated a “buy” rating and set a $12.00 price objective on shares of Altimmune in a research note on Thursday, November 14th. UBS Group assumed coverage on Altimmune in a research report on Tuesday, November 12th. They set a “buy” rating and a $26.00 price target for the company. Two investment analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Altimmune currently has an average rating of “Moderate Buy” and an average price target of $20.00.
Altimmune Price Performance
The company has a market capitalization of $642.26 million, a price-to-earnings ratio of -5.83 and a beta of 0.15. The stock has a 50-day moving average price of $7.71 and a 200-day moving average price of $7.06.
Altimmune (NASDAQ:ALT – Get Free Report) last issued its earnings results on Tuesday, November 12th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.03. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. The business had revenue of $0.01 million for the quarter. During the same period in the prior year, the company earned ($0.39) earnings per share. Equities analysts forecast that Altimmune, Inc. will post -1.36 earnings per share for the current year.
Hedge Funds Weigh In On Altimmune
Large investors have recently modified their holdings of the company. Geode Capital Management LLC lifted its position in Altimmune by 4.7% in the 3rd quarter. Geode Capital Management LLC now owns 1,668,004 shares of the company’s stock valued at $10,244,000 after acquiring an additional 74,194 shares in the last quarter. Bellevue Group AG lifted its holdings in shares of Altimmune by 43.9% in the third quarter. Bellevue Group AG now owns 863,660 shares of the company’s stock valued at $5,303,000 after purchasing an additional 263,660 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Altimmune by 142.9% during the second quarter. Dimensional Fund Advisors LP now owns 570,174 shares of the company’s stock valued at $3,791,000 after buying an additional 335,444 shares during the last quarter. BBR Partners LLC boosted its position in shares of Altimmune by 4.5% during the second quarter. BBR Partners LLC now owns 374,784 shares of the company’s stock valued at $2,492,000 after buying an additional 16,271 shares during the last quarter. Finally, SG Americas Securities LLC grew its holdings in Altimmune by 542.8% during the second quarter. SG Americas Securities LLC now owns 254,571 shares of the company’s stock worth $1,693,000 after buying an additional 214,968 shares in the last quarter. 78.05% of the stock is currently owned by institutional investors.
Altimmune Company Profile
Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company’s lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.